A Phase 2, Randomized, Double-blind Study of Adjuvant V940 (mRNA-4157) + Pembrolizumab (MK-3475) vs. Placebo + Pembrolizumab for High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC) Post-Radical Resection
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Cancer Research -
Location
-
Principal Investigator
-
Sponsor
Merck
To compare V940 plus pembrolizumab to
placebo plus pembrolizumab with respect to DFS. Hypothesis (H1): V940 plus pembrolizumab is superior to placebo plus pembrolizumab with respect to DFS as assessed by the investigator
Enrollment Form
This study is currently enrolling.